6 [8] W. A. Woodward, V. Vinh-Hung, N. T. Ueno et al., “Prognostic value of nodal ratios in node-positive breast cancer,” Journal of Clinical Oncology, vol. 24, no. 18, pp. 2910–2916, 2006. [9] E. Yildirim and U. Berberoglu, “Lymph node ratio is more valuable than level III involvement for prediction of outcome in node-positive breast carcinoma patients,” World Journal of Surgery, vol. 31, no. 2, pp. 276–289, 2007. [10] B. Keam, S. A. Im, H. J. Kim et al., “Clinical signiﬁcance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy,” Breast Cancer Research and Treatment, vol. 116, no. 1, pp. 153–160, 2009. [11] P. Tai, K. Joseph, E. Sadikov, S. Mahmood, F. Lien, and E. Yu, “Nodal ratios in node-positive breast cancer-long- term study to clarify discrepancy of role of supraclavicular and axillary regional radiotherapy,” International Journal of Radiation Oncology Biology Physics, vol. 68, no. 3, pp. 662–666, 2007. [12] S. A. Joslyn and B. R. Konety, “Eﬀect of axillary lymphadenec- tomy on breast carcinoma survival,” Breast Cancer Research and Treatment, vol. 91, no. 1, pp. 11–18, 2005. [13] K. A. Vanderveen, P. D. Schneider, V. P. Khatri, J. E. Goodnight, and R. J. Bold, “Upstaging and improved survival of early breast cancer patients after implementation of sentinel node biopsy for axillary staging,” Annals of Surgical Oncology, vol. 13, no. 11, pp. 1450–1456, 2006. [14] J. C. Tille, J. F. Egger, M. C. Devillaz, G. Vlastos, and M. F. Pelte, “Frozen section in axillary sentinel lymph nodes for diagnosis of breast cancer micrometastasis,” Anticancer Research, vol. 29, no. 11, pp. 4711–4716, 2009. [15] D. L. Weaver, “Pathology evaluation of sentinel lymph nodes in breast cancer: protocol recommendations and rationale,” Modern Pathology, vol. 23, no. 2, pp. S26–S32, 2010. [16] American Joint Committee on Cancer (AJCC) Cancer Staging Manual, Springer, New York, NY, USA, 7th edition, 2010. [17] D. F. Hayes, “Tumor node metastasis (TNM) staging clas- siﬁcation for breast cancer,” in UpToDate, B. D. Rose, Ed., UpToDate, Waltham, Mass, USA, 2010. [18] C. S. E. Bulte, M. van der Heiden-van der Loo, and A. Hennipman, “Axillary recurrence rate after tumour negative and micrometastatic positive sentinel node procedures in breast cancer patients, a population based multicenter study,” European Journal of Surgical Oncology, vol. 35, no. 1, pp. 25– 31, 2009. [19] P. J. Hainsworth, J. J. Tjandra, R. G. Stillwell et al., “Detection and signiﬁcance of occult metastases in node-negative breast cancer,” British Journal of Surgery, vol. 80, no. 4, pp. 459–463, 1993. [20] P. T. Truong, V. Vinh-Hung, G. Cserni, W. A. Woodward, P. Tai, and G. Vlastos, “The number of positive nodes and the ratio of positive to excised nodes are signiﬁcant predictors of survival in women with micrometastatic node-positive breast cancer,” European Journal of Cancer, vol. 44, no. 12, pp. 1670– 1677, 2008. [21] M. de Boer, C. H. M. van Deurzen, J. A. A. M. van Dijck et al., “Micrometastases or isolated tumor cells and the outcome of breast cancer,” The New England Journal of Medicine, vol. 361, no. 7, pp. 653–663, 2009. [22] S. L. Chen, F. M. Hoehne, and A. E. Giuliano, “The prognostic signiﬁcance of micrometastases in breast cancer: a SEER population-based analysis,” Annals of Surgical Oncology, vol. 14, no. 12, pp. 3378–3384, 2007. [23] D. Grabau, M. B. Jensen, F. Rank, and M. Blichert-Toft, “Axillary lymph node micrometastases in invasive breast Pathology Research International cancer: national ﬁgures on incidence and overall survival,” APMIS, vol. 115, no. 7, pp. 828–837, 2007. [24] G. P. Kuijt, A. C. Voogd, L. V. van de Poll-Franse, L. J. E. E. Scheijmans, M. W. P. M. van Beek, and R. M. H. Roumen, “The prognostic signiﬁcance of axillary lymph-node micrometastases in breast cancer patients,” European Journal of Surgical Oncology, vol. 31, no. 5, pp. 500–505, 2005. [25] D. C. Maibenco, G. W. Dombi, T. Y. Kau, and R. K. Severson, “Signiﬁcance of micrometastases on the survival of women with T1 breast cancer,” Cancer, vol. 107, no. 6, pp. 1234–1239, 2006. [26] Y. G. Fan, Y. Y. Tan, C. T. Wu et al., “The eﬀect of sentinel node tumor burden on non-sentinel node status and recurrence rates in breast cancer,” Annals of Surgical Oncology, vol. 12, no. 9, pp. 705–711, 2005. [27] C. E. Cox, J. V. Kiluk, A. I. Riker et al., “Signiﬁcance of sentinel lymph node micrometastases in human breast cancer,” Journal of the American College of Surgeons, vol. 206, no. 2, pp. 261– 268, 2008. [28] P. D. Gobardhan, S. G. Elias, E. V. E. Madsen et al., “Prognostic value of micrometastases in sentinel lymph nodes of patients with breast carcinoma: a cohort study,” Annals of Oncology, vol. 20, no. 1, pp. 41–48, 2009. [29] M. Colleoni, N. Rotmensz, G. Peruzzotti et al., “Size of breast cancer metastases in axillary lymph nodes: clinical relevance of minimal lymph node involvement,” Journal of Clinical Oncology, vol. 23, no. 7, pp. 1379–1389, 2005. [30] A. J. Maaskant-Braat, L. V. van de Poll-Franse, A. C. Voogd et al., “SN micrometastases in breast cancer do not aﬀect prognosis, a population-based study,” Breast Cancer Research and Treatment. In press. [31] L. H. Sobin and C. Wittekind, Eds., TNM Classiﬁcation of Malignant Tumours, Wiley-Liss, New York, NY, USA, 6th edition, 2002. [32] J. M. Cordero Garcı´a, M. Delgado Portela, A. M. Garcı´a Vicente et al., “Micrometastasis in the sentinel node and axillary lymph node macrometastasis in breast cancer,” Revista Espanola de Medicina Nuclear, vol. 29, no. 3, pp. 122–126, 2010. [33] G. Houvenaeghel, C. Nos, H. Mignotte et al., “Micrometas- tases in sentinel lymph node in a multicentric study: predictive factors of nonsentinel lymph node involvement—Groupe des Chirurgiens de la Federation des Centres de Lutte Contre Le Cancer,” Journal of Clinical Oncology, vol. 24, no. 12, pp. 1814– 1822, 2006. [34] E. M. Barbosa, A. A. R. F. Francisco, J. T. Araujo Neto, E. M. F. Alves, M. G. M. Tavares, and J. C. S. G o´es, “Clinicopathological predictor factors of axillary involvement in patients with metastatic breast cancer in the sentinel lymph node,” Revista Brasileira de Ginecologia e Obstetricia, vol. 32, no. 3, pp. 144– 149, 2010. [35] S. Kumar, M. Bramlage, L. M. Jacks et al., “Minimal disease in the sentinel lymph node: how to best measure sentinel node micrometastases to predict risk of additional non-sentinel lymph node disease,” Annals of Surgical Oncology, vol. 17, no. 11, pp. 2909–2919, 2010. [36] W. P. Olszewski, A. Szumera-Ciec´kiewicz, J. Piechocki, E. Towpik, and W. T. Olszewski, “The characteristics of the sentinel lymph node metastasis in predicting the axillary lymph node status in patients with breast carcinoma,” Polish Journal of Pathology, vol. 60, no. 3, pp. 138–143, 2009. [37] K. J. van Zee, D. M. E. Manasseh, J. L. B. Bevilacqua et al., “A nomogram for predicting the likelihood of additional nodal